Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Maria Victoria Hinckelmann *Université de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID https://orcid.org/0000-0003-0138-2613
Aline Dubos *Université de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0000-0001-9279-0166
Victorine ArtotUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0009-0002-9694-9538
Gabrielle RudolfUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.
Thu Lan NguyenUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.
Peggy TillyUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0000-0002-4675-2035
Valérie NalessoUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.
Maria Del Mar Muniz MorenoUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.
Marie-Christine BirlingUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0000-0002-3372-8108
Juliette D GodinUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0000-0001-6559-1065
Véronique BraultUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France.ORCID http://orcid.org/0000-0002-1418-5849
Yann HeraultUniversité de Strasbourg, Centre National de la Recherche Scientifique (CNRS) UMR7104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1258, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch-Graffenstaden, F-67404, France. herault@igbmc.fr.ORCID http://orcid.org/0000-0001-7049-6900
Funding
Agence Nationale de la Recherche (French National Research Agency) DYRK-DOWNFondation Jérôme Lejeune (Jérôme Lejeune Foundation) 1647
6 · The paper itself
Abstract
Interneuron development is a crucial step of brain corticogenesis. When affected it often leads to brain dysfunctions like epilepsy, intellectual disabilities and autism spectrum disorder. Such defects are observed in the DYRK1A-haploinsufficiency syndrome, caused by mutations in DYRK1A, and commonly associated to cortical excitatory/inhibitory imbalance. However, how this imbalance is established in this syndrome remains elusive. Here, using mouse models and live imaging, we demonstrate that Dyrk1a specifically regulates the development of the cortical GABAergic system. We show that, unlike projection excitatory neurons, interneuron tangential migration relies on Dyrk1a dosage and kinase activity. We further reveal that Dyrk1a regulates actomyosin cytoskeleton remodeling during interneuron migration. Interestingly, mice with heterozygous inactivation of Dyrk1a in interneurons exhibited decreased interneuron density together with behavioral defects and epileptic activity, recapitulating phenotypes observed in human patients. Altogether, these data highlight the critical role of Dyrk1a in the development of the GABAergic system and the pathophysiology of DYRK1A-haploinsufficiency syndrome.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.